Lumos Pharma, Inc. Overview
Pro stress-test →Lumos Pharma is a clinical stage biopharmaceutical company based in Austin, Texas focused on the development and commercialization of therapeutics for rare diseases. The company's lead therapeutic candidate, LUM-201, is a novel oral growth hormone secretagogue seeking to transform the $4.5B global GH market from injectable to oral therapy, and is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD).
Strategic Profile
Pro stress-test →Lumos Pharma has raised a total of $48M across 9 funding rounds. Topline data from Phase 2 OraGrowtH210 and OraGrowtH212 trials of LUM-201 in PGHD met all primary and secondary endpoints (October 2025), positioning the company to advance toward regulatory submissions. The company is led by a management team with longstanding experience in rare disease drug development.
Competitive Landscape
Pro stress-test →Lumos Pharma competes in the rare disease therapeutics and pediatric growth hormone deficiency treatment space. Top competitors include Alnylam, BridgeBio and Alexion. The company's oral formulation of GH secretagogue positions it as an alternative to current injectable GH therapies, offering potential commercial advantage through improved patient compliance and quality of life.
Industry Context
Lumos Pharma, Inc. operates in Rare disease biopharmaceuticals.
Key facts
Founded: 1999 · Headquarters: Austin, Texas, US · Employees: 47 · Revenue: $2.05M (2023) · Market cap: N/A